Endologix, Inc (NASDAQ: ELGX) shares rose Tuesday after the company reported positive results of Encore analysis of several prospective clinical trials and registries studying Polymer Endovascular Aneurysm Repair.
ENCORE is a pooled, retrospective analysis of six prospectively enrolled clinical trials and registries of Ovation Abdominal Stent Graft Systems encompassing 1,296 patients, 160 centers and 339 investigators in the U.S., Europe and Latin America.
This contemporary analysis standardizes outcome variables across each study. The data is a mix of real world registry and controlled data, and all endpoints are presented using Kaplan-Meier survival estimates.
At five years, the ENCORE analysis included the following results for Ovation based on the available data: 99.1% freedom from AAA-related mortality; 99.0% freedom from re-intervention for Type 1a endoleak, and 99.7% freedom from rupture
Endologix Chief Medical Officer Matt Thompson said, "With ENCORE, our objective was to conduct a rigorous, global evaluation of the available Polymer EVAR clinical data, which includes nearly 1,300 patients, and to share the consolidated results with physicians worldwide.
"We look forward to sharing additional analyses from the ENCORE data set in the future, and we’d like to thank all of the clinical investigators who participated in the underlying studies that are the basis for the ENCORE analysis."
Endologix develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement.
Shares gathered eight cents Tuesday, or 1.9%, to $4.24
